Skip links

We Are:

Committed To Creating a New and Better Era in Ocular Drug Delivery.

Developing an Innovative Drug Eluting Contact Lens Platform to Treat Eye Diseases through a targeted, tailored, and sustained drug delivery approach.

Bringing this highly anticipated innovation to eye disease treatment by leveraging an experienced leadership team.

Creating a New and Better Era in Ocular Drug Treatment

Use Cases -Potential

$1.5B Markets

FDA Approved Senofilcon A Contact Lens

FDA Approved Drugs

Indication – 5th year Market Share

Infection -15%

Glaucoma - 8%

Ocular Cystinosis – 33%

Post Ocular Surgery- 16%

Corneal Defects – 5%

Rare Diseases/Myopia Control- Unknown

The Problem

Patients and Physicians have struggled with eye drop compliance & instillation issues for years - which reduce drug efficacy

Patient Compliance Issues


of subjects used drops as directed1


of patients missed 6 or more doses over a 30-day period2


of patients missed 20% of prescribed doses3

Eye Drop Instillation Issues

Drug instilled via eye drops is cleared rapidly from the eye resulting in sharp decreases in concentration in tears and tissues

Directing the bottle, shaky hand, squeezing the bottle, blinking, poor visibility of the dropper were the most common issues reported


of subjects admitted having some difficulty administrating eye drops1


of patients either missed their eye, instilled an incorrect number of drops, contaminated the bottle tip, or failed to wash their hands before instillation4

The drug concentration may drop below therapeutic levels before the next drop is instilled which could lead to bacterial growth as well as development of resistance

1.   Winfield AJ, Jessiman D, Williams A, Esakowitz L. A study of the causes of non-compliance by patients prescribed eyedrops. Br J Ophth, 1990; Aug 74 (8) 477-480

2.   Norell SE, Granstrom PA. Self-medication with pilocarpine among outpatients in a glaucoma clinic. Br J Ophthalmology 1980; 64: 137-41

3.   Kass MA, Meltzer DW, Gordon M, Cooper D, Goldberg J. Compliance with topical pilocarpine treatment. Am J Ophthalmology 1986; 101: 515-23

4.   Matossian C. Noncompliance with Prescribed Eyedrop Regimens among Patients Undergoing cataract Surgery-Prevalence, Consequences and Solutions. US Ophthalmic Review. 2020;13(1):18-22 DOI: https//

The New Patient Treatment Paradigm

Through a new treatment paradigm, the patient will no longer require frequent trips to the pharmacy or frequent eye drop instillations which interrupt daily activities, place inconvenient burden on the patient and make compliance very challenging. The issues of compliance and eye drop instillations are eliminated, providing significant improvement over the current eye drop technology.

Eye Physician Visit

Patient has an infection


Post exam patient receives MoxiLensTM lens

2nd Patient Visit

After 1 to 5 days patient returns for exam and further treatment if needed – Current MoxiLensTM is removed & a new MoxiLensTM is inserted if needed

The Freya Solution

Removing compliance and drop instillation barriers with Innovative Drug Eluting Contact Lens Platform

The Sustained release of medication from the contact lens eliminates the need for multiple drop instillations

  • No compliance issues
  • No instillation issues

A Higher concentration of preservative-free medication is delivered to the eye as the medication is released directly onto the cornea

0  Milion +
0  Milion +

Bacterial Conjunctivitis Infections per Year

Lead Market

Introducing the First Antibiotic Bandage Contact Lens - MoxiLensTM

MoxiLensTM : A Simple Answer

One or Two lenses vs 21 “day interrupting” eye drop instillations over 7 days


MoxiLensTM : A Simple Answer

One or Two lenses vs 21 “day interrupting” eye drop instillations over 7 days

Typical Dosage & Administration: 1 drop 3 times a day for 7 days


Latest news and updates

Follow Us on Twitter

Latest news and updates

Visit App Instagram

Latest news and updates

Telegram Channel

Latest news and updates